Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.46.5.1486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Altered exosomal miRNA profiles in patients with paraneoplastic cerebellar degeneration.
Ann Clin Transl Neurol
December 2024
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Article Synopsis
- The study explores the relationship between ovarian cancer (OC) and anti-Yo-associated paraneoplastic cerebellar degeneration (PCD), focusing on changes in exosomal microRNA (miRNA) profiles in OC patients with PCD compared to healthy individuals and those without PCD.
- Serum exosomes from three groups (OC with PCD, OC without PCD, and healthy controls) were analyzed, revealing 103 differentially expressed miRNAs in PCD patients versus OC patients without PCD, and 139 versus healthy controls.
- Key miRNAs such as miR-486-5p and miR-21-5p showed potential as biomarkers for diagnosing PCD and indicated a link between these miRNAs and the
A case of corticobasal syndrome possibly associated with anti-Yo antibodies.
Curr Med Res Opin
October 2024
1st Department of Neurology, Aiginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Corticobasal syndrome (CBS) is a rare form of atypical parkinsonism, most commonly caused by neurodegenerative disorders. Autoimmune underlying conditions are extremely rare, and anti-Yo antibody-associated CBS has not been reported yet.
Case Report: Herein, we describe a case of a 68-year-old woman presenting with progressive dysarthria, gait instability and difficulty using her left hand with subacute deterioration during the last 3 months.
Anti-Yo antibody-associated Autoimmune Encephalitis due to Breast Adenocarcinoma in a male patient.
Fortschr Neurol Psychiatr
October 2024
Neurology, Ankara Training and Research Hospital, Ankara, Turkey.
Paraneoplastic neurological syndromes occur due to immune-mediated neuronal dysfunction secondary to systemic malignancy, and symptoms can usually be seen before malignancy. There are many subtypes that depend on the antibodies present or the proteins they target. Accurate epidemiological data are lacking as it is difficult to diagnose.
View Article and Find Full Text PDFA cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Eur J Neurol
June 2023
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Background And Purpose: Commercially available tests for Yo antibody detection have low specificity for paraneoplastic cerebellar degeneration (PCD) because these assays use cerebellar degeneration-related protein 2 (CDR2) as the antigen, not CDR2-like (CDR2L). We aimed to test the hypothesis that use of a CDR2L cell-based assay (CBA), as an additional screening technique, would increase the accuracy of Yo-PCD diagnosis.
Methods: An in-house CBA to test for anti-CDR2L antibodies was developed and used to screen sera from 48 patients with confirmed anti-Yo-associated PCD.
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.
Neurol Neuroimmunol Neuroinflamm
September 2022
From the Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon; French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon; University of Lyon, Université Claude Bernard Lyon 1; Department of Biopathology, Centre Leon Berard; INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon; Cancer Genomics Platform, Department of Translational Research, Centre Leon Berard; Synergie Lyon Cancer- Bioinformatics Platform-Gilles Thomas, Centre de Recherche en Cancérologie de Lyon; and Laboratoire d'Immunothérapie des Cancers de Lyon (LICL), France.
Article Synopsis
- Identified the role of genetic alterations in Yo antigens as a trigger for paraneoplastic cerebellar degeneration (PCD) in breast cancer, associated with the presence of anti-Yo antibodies.
- Characterized 22 breast cancers with Yo-PCD, finding that they were typically aggressive, HER2-positive, and hormone receptor-negative with distinct genetic profiles.
- Discovered significant immune responses in Yo-PCD breast cancers, including a high infiltration of immunoglobulin G-plasma cells and pathways linked to adaptive immunity, suggesting a specific cancer-related immune response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!